Natera
 
公司簡況
財務
派息紀錄
盈利預測
股權變動
ETF簡況
 
 
 
公司概覽
業務類別 Diagnostics & Research
業務概覽 Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
公司地址 13011 McCallen Pass, Building A Suite 100, Austin, TX, USA, 78753
電話號碼 +1 650 980-9190
傳真號碼 +1 650 456-2122
公司網頁 https://www.natera.com
員工數量 6140
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Mr. Michael Brophy Chief Financial Officer and Principal Accounting Officer 美元 493.25K 27/02/2026
Mr. Daniel Rabinowitz Secretary and Chief Legal Officer -- 27/02/2026
Mr. Solomon Moshkevich President, Clinical Diagnostics 美元 490.03K 24/04/2025
Mr. John Fesko Co-President and Chief Business Officer 美元 490.03K 24/04/2025
Mr. Steven Leonard Chapman Director, Chief Executive Officer and President 美元 799.95K 27/02/2026
 
董事會成員
董事會 職務 更新日期
Dr. Matthew Rabinowitz Executive Chairman of the Board 27/02/2026
Mr. Jonathan Sheena Director 27/02/2026
Dr. Monica Bertagnolli, M.D. Independent Director 27/02/2026
Ms. Ruth W. Brinkley Independent Director 27/02/2026
Dr. Rowan E. Chapman, PhD Independent Director 27/02/2026
Mr. Herm Rosenman Independent Director 27/02/2026
Dr. James I. Healy, M.D.,PhD Independent Director 24/04/2025
Mr. Steven Leonard Chapman Director, Chief Executive Officer and President 27/02/2026
Dr. Gail B. Marcus Independent Director 27/02/2026
Dr. Roy D. Baynes, M.D.,PhD Independent Director 27/02/2026
Mr. Roelof Frederik Botha Lead Independent Director 27/02/2026
 
所屬ETF (更新日期: 07/03/2026 03:30)
代號 名稱 佔比% ▼ 持有日期
BKIVBNY Mellon Innovators ETF<0.000001%16/09/2025
BKWOBNY Mellon Women's Opportunities ETF<0.000001%16/09/2025
BTALAGF U.S. Market Neutral Anti-Beta<0.000001%02/09/2025
BTXBlackRock Tech and Private Equity Term<0.000001%31/12/2025
CLSEConvergence Long/Short Equity ETF<0.000001%26/02/2026
CNAVMohr Company Nav ETF<0.000001%18/02/2026
ESMLiShares ESG Aware MSCI USA Small-Cap ETF<0.000001%28/02/2026
FBCGFidelity Blue Chip Growth ETF<0.000001%30/09/2025
FCTRFirst Trust Lunt US Factor Rotation ETF<0.000001%04/02/2026
FDIFFidelity Disruptors ETF<0.000001%02/02/2026
FFTYInnovator IBD® 50 ETF<0.000001%09/02/2026
FMTMMarketDesk Focused U.S. Momentum ETF<0.000001%30/12/2025
FRTYAlger Mid Cap 40 ETF<0.000001%02/10/2025
FSMDFidelity Small-Mid Multifactor ETF<0.000001%15/08/2025
GDMAGadsden Dynamic Multi-Asset ETF<0.000001%16/01/2026
GTPEGoldman Sachs MSCI Wld Priv Eq RtTrkrETF<0.000001%27/02/2026
GVIPGoldman Sachs Hedge Industry VIP ETF<0.000001%26/02/2026
HKNDHumankind US Stock ETF<0.000001%24/11/2025
HLGEHartford Longevity Economy ETF<0.000001%11/06/2025
ISCBiShares Morningstar Small-Cap ETF<0.000001%28/02/2026
  1    2    3    4    5    6    7   8    9  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.